These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8265124)

  • 21. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
    Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K
    J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of BCG immunotherapy in the management of bladder tumors].
    Samodai L; Kiss L; Kolozsy Z; Dauda G; Drinóczy M; Mohácsi L
    Orv Hetil; 1990 Aug; 131(31):1697-702. PubMed ID: 2205825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
    Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The prevention of stage-T1 superficial bladder tumors with 27 mg. of BCG weekly over 6 weeks].
    Moyano Calvo JL; Ortíz Gámiz A; Romero Díaz A; Sánchez Sánchez E; Blanco Palenciano E; Arribas Rodríguez JM; Castiñeiras Fernández J
    Arch Esp Urol; 1999 Sep; 52(7):760-8. PubMed ID: 10540766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [5-year experience with BCG immunoprophylaxis in superficial bladder cancer].
    Romics I; Bach D; Rüssel C
    Orv Hetil; 1992 Sep; 133(36):2275-6, 2279-81. PubMed ID: 1408061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The prevention of the recurrence of stage pTa bladder tumors using intravesical instillation of BCG].
    Wetzel O; Glemain P; Bouchot O; Guillonneau B; Baron M; Buzelin JM; Auvigne J
    Prog Urol; 1993; 3(4):595-607. PubMed ID: 8401620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term experience with prophylactic BCG therapy of high risk patients with superficial bladder tumors].
    Prekopp G; Kiss T
    Orv Hetil; 1997 Mar; 138(9):531-5. PubMed ID: 9102628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in the cytokine concentration during immunotherapy of superficial bladder tumors].
    Somogyi L; de Boer EC; de Ruiter GJ; de Reijke TM; Kurth KH; Schamhart DH
    Orv Hetil; 1998 Jan; 139(2):67-9. PubMed ID: 9451905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.